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Background: Morbidity and mortality related to Prescription Opioid Analgesics (POAs) have been rising sharply in
North America. Non-Medical Prescription Opioid Use (NMPOU) in the general population is a key indicator of
POA-related harm, yet the role of question item design for best NMPOU prevalence estimates in general population
surveys is unclear, and existing NMPOU survey data for Canada are limited.
Methods: We tested the impact of different NMPOU question items by comparing an item in the 2008 and 2009
(N = 2,017) samples of the CAMH Monitor surveys – an Ontario adult general population survey – with a newly
developed item used in the 2010 (N = 2,015) samples of the Centre for Addiction and Mental Health (CAMH)
Monitor surveys. To control for a potential difference in the population demographics between surveys, we
adjusted for gender, age, region, income, prescription opioid use, cigarette smoking, weekly binge drinking,
cannabis use in the past three months, and psychological distress in our analyses.
Results: The prevalence of NMPOU as measured by the 2008 and 2009 CAMH monitor (2.0% [95% CI: 1.2% to
2.8%]) was significantly different when compared to the prevalence of NMPOU as measured by the 2010 CAMH
monitor (7.7% [95% CI: 6.3% to 9.2%]) (p < 0.001). This difference was also found when stratifying our analysis by sex
(p < 0.001) and when adjusting for all potential confounding covariates.
Conclusion: It is highly unlikely that the extensive NMPOU prevalence differences observed from the different
survey items reflect an actual increase of NMPOU or changes in NMPOU determinants, but rather point to
measurement effects. It appears that we currently do not have accurate estimates of NMPOU in the Canadian
general population, even though these estimates are needed to guide and implement targeted interventions.
Given the current substantial morbidity and mortality impact of NMPOU, there is an urgent need to systematically
develop, validate and standardize NMPOU items for future general population surveys in Canada.
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In Canada and the United States (U.S.), levels of Pre-
scription Opioid Analgesic (POA) use have been rising
since 2000; globally, Canada and the U.S. have the high-
est levels of POA use [1]. In this context, POA-related
morbidity and mortality levels have also increased in
recent years [2-6], constituting a major public health
problem.
A key epidemiological indicator of POA-related pro-
blems is the prevalence of Non-Medical Prescription
Opioid Use (NMPOU), which is defined as using POAs
when they are not prescribed by a physician, or using
POAs for purposes other than as prescribed; the defi-
nition of NMPOU excludes the underuse of POAs. The
prevalence of NMPOU is strongly correlated to levels of
POA-related morbidity and mortality [6], and hence the
prevalence of NMPOU in the general population needs
to be accurately identified for targeted preventive inter-
ventions [6-9].
NMPOU, can be defined and operationalized in diffe-
rent ways. For example, the Canadian Alcohol and Other
Drug Use Monitoring Survey (CADUMS) initially sur-
veyed NMPOU in the Canadian general adult population
(15+ years) in 2008 based on the following questions: 1)
“During the past 12 months, did you ever use pain relie-
vers for the feelings [they] caused or to get high?”, and/
or 2) Were the pain relievers used during the past
12 months obtained from i) “a prescription written for
someone else such as a family member or a friend,” ii)
“bought from someone else, without a prescription,” iii)
“from any other source” [10]. On this basis, the
CADUMS found an NMPOU prevalence of 0.4%, which
amounted to about one-tenth of the NMPOU prevalence
of 4.8% estimated for the United States (U.S.) general
youth and adult (12+ years) population in 2008 by the
National Survey on Drug Use and Health (NSDUH)
[11,12].
In contrast to the CADUMS, NMPOU is defined in the
NSDUH as having provided the answer “yes” to the ques-
tion: “Have you ever, even once, used (name of prescrip-
tion opioid) that was not prescribed for you or that you
took only for the experience or feeling it caused?” [12].
Given the amount of POAs that are prescribed in Canada
and in the U.S., and the association between `POA use
and NMPOU [13], NMPOU prevalence estimates for
Canada should be approximately half the prevalence of
NMPOU in the U.S. Differences in the prevalence esti-
mates of NMPOU obtained from the CADUMS and from
the NSDUH may be due in part to variations in the formu-
lation of questions asked in each of these surveys which re-
sult in differing responses. As measurement differences in
NMPOU have not been investigated, there is a timely need
and opportunity to investigate estimate variations that may
arise from differences in how NMPOU is operationalized.Methods
To examine potential measurement effects for asses-
sing the prevalence of NMPOU in Canada, we tested
an alternative NMPOU item constructs in the Centre
for Addiction and Mental Health (CAMH) Monitor
surveys [14,15].The 2008, 2009 and 2010 CAMH
Monitor surveys employed a two-stage, probability
sample based, computer-assisted telephone intervie-
wing, random-digit dialing method, and sampled the
Ontario general adult population (18+ years). Each
month of the survey a sampling frame of all active
area codes and exchanges in Ontario was obtained
from ATI long lines tape. Telephone numbers from
this source, as well as telephone numbers between or
on either side of listed numbers were included in the
sampling frame. This method allowed for any person
with a home phone (listed or unlisted) or a cellphone
to be included in the sampling frame; however, a pro-
portion of people with an unlisted number and/or a
cellphone were not included in the sampling frame.
The sampling frame was then stratified into regions
(based on counties) as follows: Toronto, Central West
Ontario, Central East Ontario, West Ontario, East On-
tario, and North Ontario (see [14-16] for the exact
counties included within each region). Within each
stratum, a random sample of telephone numbers was
selected with equal probability. To increase the re-
sponse rate in the stratum of Toronto, a letter was
sent to the selected household informing them that
they would be contacted and describing the history
and objectives of the CAMH Monitor survey. Within
selected households, the respondent who was 18 years
of age or older, who had the most recent birthday
of the eligible household members, and who could
complete the interview in either English or French
was selected to participate in the survey. A minimum
of 12 call-backs were placed to unanswered numbers
and all households who refused to participate on the
first contact were re-contacted and asked again to par-
ticipate. No incentive was offered for participation.
The procedures and interviews of each cycle of the
CAMH Monitor surveys were approved by the CAMH
Research Ethics Board [14,15].
NMPOU questions in the 2008 and 2009 waves of
the CAMH Monitor surveys were asked from July to
December, whereas the 2010 NMPOU data were col-
lected from January to December of the respective year.
Response rates for the CAMH Monitor surveys were
calculated using the method proposed by the American
Association for Public Opinion Research (response rate
calculation #3) which takes into account in the response
rate calculation the number of telephone numbers which
may be eligible to be included in the survey [14-16]. This
formula for calculating the response rate is as follows:
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I þ Pð Þ þ Rþ NCð Þ þ e UHð Þ
where I represents the number of completions, P repre-
sents the number of partial completions, R represents
the refusals/breakoffs, NC represents non-contacts, e
represents the estimated proportion of cases of un-
known eligibility that are eligible, and UH represents the
number of telephone numbers which may be eligible to
be included in the survey.
In the 2008, 2009 and 2010 waves of the CAMHMonitor
surveys POAs were defined as “pain relievers that are
obtained by a prescription from a doctor or dentist such as
Percocet, Percodan, Demerol, OxyContin, Tylenol #3 or
other products or pain relievers with codeine that are
obtained in a pharmacy. Some people use these medica-
tions to treat pain resulting from an illness, injury.”
NMPOU in the 2008 and 2009 waves of the CAMH Moni-
tor surveys was measured similarly to the CADUMS ques-
tions described above as follows: 1) “Thinking about all the
pain relievers you have used during the past 12 months did
you get any of them” i) “from a prescription written for
someone else such as a family member or a friend”,
ii) “bought from someone else, without a prescription”
and/or iii) “from any other source (defined as a source
other than the previously mentioned sources and a pre-
scription written for you),” and 2) “During the past
12 months, did you ever use pain relievers for the feelings
it caused or to get high?” The alternative NMPOU item
tested in the 2010 wave of the CAMH Monitor survey was
based on the question: “In the past 12 months how many
times, if at all, have you used any such pain relievers with-
out a prescription or without a doctor telling you to take
them?”
The items used in the 2008 and 2009 waves of the
CAMH Monitor surveys were initially pretested with
25 respondents in November 2007 and included as a
pilot study in December of the 2007 wave of the
CAMH Monitor survey (N = 175). Applicable questions
were asked at the end of the POA items in the
2009 cycle of the CAMH Monitor survey to evaluate
the response process; 96.4% of respondents declared
that the questions on POA use were not difficult to
understand, and 96.1% of respondents did not need the
questions to be repeated to them before answering
[17]. The items used in the 2010 wave of the CAMH
Monitor survey were also initially asked in the 2007
and the 2009 cycles of the Ontario Student Drug Use
and Health Survey. These questions were revised for
the 2010 wave of the CAMH Monitor survey based on
pretesting which confirmed item comprehension and
feasibility.For our analysis of the difference in the measurement
effect of the alternative NMPOU survey items on the esti-
mated prevalence of NMPOU, we controlled for the fol-
lowing demographic variables: age (grouped into three
categories: 18–29, 30–54, 55+), region (living in Toronto,
the rest of Ontario), and household income (<$30,000,
$30,000–79,000, $80,000+, not stated). The substance use
variables we controlled for in our analysis were tobacco
use (defined as either daily or occasional (during the last
12 months) cigarette smoking), weekly binge drinking
(defined as drinking five or more drinks on one occasion
at least once a week in the previous 12 months), and can-
nabis use (defined as using cannabis at least once in the
previous 12 months).
We also controlled for psychological distress, as mea-
sured by the 12-item General Health Questionnaire
(GHQ-12). The GHQ-12 is a screening instrument that
evaluates depression/anxiety and problems with social
functioning [18] and we used a cut-off score of 3 or
more on the GHQ-12 as an indication of elevated psy-
chological distress.
All statistical analyses were performed using population
expansion weights. Population expansion weights were
constructed using census data from Statistics Canada on
the number of people living in each stratum by age
(using the age categories of 18-24, 25-44, 45-64, 65+)
and by sex [14-16]. Significant differences between preva-
lence estimates were calculated using chi-square tests
with a second-order Rao-Scott adjustment for survey
data for the unadjusted analysis [19]. For the unadjusted
and adjusted regression analyses, we employed a general
linear model adjusted for survey design. All statistics
were performed using the statistical software package R
version 2.15.1 [20], and the statistical software package
Survey (a statistical package for R) [21].
Results
The CAMH Monitor survey response rates were 56.6%
for July to December in 2008, 57.5% for July to December
in 2009, and 50.6% for January to December in 2010. The
NMPOU items run in the 2008 and 2009 waves of the
CAMH Monitor surveys had valid data for n = 1,021
(effective response rate of 56.1%) for 2008 and n = 996
(effective response rate of 57.1%) for 2009 respectively.
The NMPOU item run in the 2010 wave of the CAMH
Monitor survey had valid data for n = 2,015 (effective
response rate of 50.2%). The response rates for the 2008,
2009 and 2010 waves of the CAMH Monitor surveys did
not vary significantly by month.
Table 1 outlines the prevalence estimates for the
different NMPOU items run in the 2008 and 2009
CAMH Monitor survey samples and in the 2010
CAMH Monitor survey sample. Table 2 outlines the
prevalence of NMPOU by gender. The prevalence of
Table 1 Characteristics of Ontario adults (18+ years) as measured by the 2008, 2009 and 2010 CAMH Monitor surveys
CAMH Monitor 2008 and 2009 CAMH Monitor 2010
n Point estimate 95% Confidence intervals n Point estimate 95% Confidence intervals
Gender
Men 896 50.5% (47.8% to 53.2%) 887 49.8% (47.1% to 52.5%)
Women 1134 49.5% (46.8% to 52.2%) 1137 50.2% (47.5% to 52.9%)
Age (years)
18–29 295 26.7% (23.8% to 29.5%) 319 28.2% (25.4% to 31.1%)
30–54 826 43.1% (40.4% to 45.8%) 756 39.6% (36.0% to 42.3%)
55+ 844 30.2% (28.0% to 32.5%) 912 32.1% (29.8% to 34.4%)
Region
Toronto 317 21.1% (19.2% to 23.0%) 332 21.9% (19.9% to 23.8%)
Rest of Ontario 1713 78.9% (77.0% to 80.8%) 1692 78.1% (76.2% to 80.1%)
Income
<$30,000 250 8.5% (7.1% to 9.9%) 242 8.7% (7.2% to 10.1%)
$30,000 to $49,999 254 10.4% (8.9% to 11.9%) 269 10.4% (9.0% to 11.9%)
$50,000 to $79,999 390 19.2% (17.2% to 21.3%) 370 17.7% (15.7% to 19.7%)
$80,000+ 619 35.0% (32.4% to 37.6%) 670 38.7% (36.1% to 41.4%)
Not stated 517 26.9% (24.4% to 29.3%) 473 24.5% (22.1% to 26.8%)
Prescription opioid use
Yes 475 21.3% (19.1% to 23.4%) 485 23.1% (20.8% to 25.3%)
No 1543 78.7% (76.6% to 80.9%) 1515 76.9% (74.7% to 79.2%)
Non-medical prescription opioid use
Yes 40 2.0% (1.2% to 2.8%) 143 7.7% (6.3% to 9.2%)
No 1977 98.0% (97.2% to 98.8%) 1872 92.3% (90.8% to 93.7%)
Cigarette smoking
Current 399 18.9% (16.8% to 21.0%) 373 19.4% (17.2% to 21.6%)
Former 654 28.2% (25.9% to 30.4%) 654 28.2% (25.9% to 30.6%)
Never smoker 973 52.9% (50.2% to 55.6%) 991 52.4% (49.7% to 55.1%)
Weekly binge drinking
Yes 133 7.9% (6.4% to 9.4%) 144 8.2% (6.7% to 9.8%)
No 1883 92.1% (90.6% to 93.6%) 1866 91.8% (90.2% to 93.3%)
Cannabis use (past 3 months)
Yes 148 10.1% (8.3% to 12.0%) 186 12.0% (10.0% to 14.0%)
No 1876 89.9% (88.0% to 91.7%) 1838 88.0% (86.0% to 90.0%)
Psychological distress (GHQ 3+)
Yes 284 13.4% (11.5% to 15.2%) 277 14.6% (12.6% to 16.6%)
No 1743 86.6% (84.8% to 88.5%) 1746 85.4% (83.4% to 87.4%)
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the 2008 and 2009 waves of the CAMH Monitor sur-
veys was 2.0% (95% Confidence Interval (CI): 1.2% to
2.8%) (2.3% for 2008 and 1.7% for 2009), and was 7.7%
(95% CI: 6.3% to 9.2%) in 2010 as measured by the 2010
wave of the CAMH Monitor survey. This difference in
the measured prevalence of NMPOU in the 2008 and2009 CAMH Monitor surveys and in the 2010 CAMH
Monitor survey was significant (p <0.001). Significant dif-
ferences between the NMPOU items were also observed
when the analysis was stratified by sex (p <0.001 for
women and p <0.001 for men). The Additional file 1: Web
appendix outlines these prevalence estimates using no
weights.
Table 2 Characteristics of Ontario adults (18+ years) as measured by the 2008, 2009 and 2010 CAMH Monitor surveys
by gender
Women Men
CAMH Monitor 2008 and 2009 CAMH Monitor 2010 CAMH Monitor 2008 and 2009 CAMH Monitor 2010
n Point
estimate
95%
Confidence
intervals
n Point
estimate
95%
Confidence
intervals
n Point
estimate
95%
Confidence
intervals
n Point
estimate
95%
Confidence
intervals
Age (years)
18–29 147 26.2% (22.1% to 30.2%) 157 24.5% (21.0% to 28.0%) 148 27.1% (23.2% to 31.1%) 162 32.0% (27.7% to 36.3%)
30–54 454 42.9% (39.2% to 46.6%) 414 40.5% (37.0% to 44.0%) 372 43.3% (39.4% to 47.2%) 342 38.8% (34.9% to 42.6%)
55+ 488 30.9% (27.9% to 34.0%) 545 35.0% (31.8% to 38.1%) 356 43.3% (40.0% to 46.6%) 367 38.8% (35.5% to 42.0%)
Region
Toronto 179 21.7% (18.7% to 24.8%) 196 23.6% (20.7% to 26.5%) 138 20.5% (17.4% to 23.6%) 136 20.1% (16.9% to 23.4%)
Rest of
Ontario
955 78.3% (75.2% to 81.3%) 941 76.4% (73.5% to 79.3%) 758 79.5% (76.4% to 82.6%) 751 79.9% (76.6% to 83.1%)
Income
<
$30,000
163 9.8% (7.9% to 11.7%) 156 9.5% (7.7% to 11.4%) 87 7.2% (5.3% to 9.2%) 86 7.8% (5.6% to 10.0%)
$30,000
to
$49,999
139 10.1% (8.1% to 12.1%) 164 11.4% (9.3% to 13.4%) 115 10.7% (8.4% to 12.9%) 105 9.5% (7.4% to 11.6%)
$50,000
to
$79,999
216 19.5% (16.7% to 22.3%) 189 16.7% (14.1% to 19.3%) 174 19.0% (16.0% to 12.9%) 181 18.7% (15.7% to 21.8%)
$80,000
+
290 30.7% (27.2% to 34.3%) 336 35.3% (31.8% to 38.7%) 329 19.0% (15.2% to 22.7%) 334 18.7% (14.7% to 22.7%)
Not
stated
326 29.9% (26.4% to 33.3%) 292 27.1% (23.9% to 30.4%) 191 23.9% (20.4% to 27.4%) 181 21.8% (18.3% to 25.2%)
Prescription opioid use
Yes 279 22.7% (19.6% to 25.7%) 293 24.7% (21.7% to 27.7%) 196 19.9% (16.9% to 22.9%) 192 21.4% (18.1% to 24.8%)
No 848 77.3% (74.3% to 80.4%) 829 75.3% (72.3% to 78.3%) 695 80.1% (77.1% to 83.1%) 686 78.6% (75.2% to 81.9%)
Non-medical prescription opioid use
Yes 20 1.6% (0.8% to 2.5%) 77 7.4% (5.5% to 9.3%) 20 2.4% (1.0% to 3.7%) 66 8.1% (5.9% to 10.3%)
No 1106 98.4% (97.5% to 99.2%) 1058 92.6% (90.7% to 94.5%) 871 97.6% (96.3% to 99.0%) 814 91.9% (89.7% to 94.1%)
Cigarette smoking
Current 194 15.2% (12.6% to 17.7%) 188 15.7% (13.1% to 18.2%) 205 22.6% (19.3% to 25.9%) 185 23.1% (19.6% to 26.7%)
Former 342 25.9% (22.9% to 28.9%) 340 26.1% (23.1% to 29.0%) 312 30.4% (27.0% to 33.8%) 314 30.4% (26.9% to 34.0%)
Never
smoker
595 59.0% (55.4% to 62.5%) 607 58.3% (54.8% to 61.7%) 378 47.0% (43.0% to 50.9%) 384 46.4% (42.4% to 50.5%)
Weekly binge drinking
Yes 27 2.9% (1.5% to 4.4%) 29 3.3% (1.9% to 4.6%) 106 12.8% (10.2% to 15.5%) 115 13.2% (10.4% to 16.0%)
No 1102 97.1% (95.6% to 98.5%) 1102 96.7% (95.4% to 98.1%) 781 87.2% (84.5% to 89.8%) 764 86.8% (84.0% to 89.6%)
Cannabis use (past 3 months)
Yes 46 6.1% (4.0% to 8.2%) 61 6.3% (4.5% to 8.2%) 102 14.1% (11.1% to 17.0%) 125 17.7% (14.2% to 21.1%)
No 1084 93.9% (91.8% to 96.0%) 1076 93.7% (91.8% to 95.5%) 792 85.9% (83.0% to 88.9%) 762 82.3% (78.9% to 85.8%)
Psychological distress (GHQ 3+)
Yes 178 16.3% (13.5% to 19.1%) 180 16.8% (14.0% to 19.5%) 106 10.5% (8.2% to 12.9%) 97 12.4% (9.5% to 15.3%)
No 954 83.7% (80.9% to 86.5%) 957 83.2% (80.5% to 86.0%) 789 89.5% (87.1% to 91.8%) 789 87.6% (84.7% to 90.5%)
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ratios for NMPOU by survey and gender. When compar-
ing the 2008 and 2009 waves to the 2010 wave of the
CAMH Monitor surveys, the odds of NMPOU increased
by 3.99 (95% CI: 2.52 to 6.31) when not adjusting for any
covariates, and by 4.12 (95% CI: 2.66 to 6.37) when
adjusting for all confounding covariates. The interaction
between gender and survey year on the odds of NMPOU
was not found to be significant (p > 0.10).Discussion
Our results suggest that NMPOU survey estimates differ
markedly depending on the question items used. The
estimated prevalence of NMPOU in Ontario is
approximately 210,000 people (derived from population
estimates of Ontario in 2010) when based on the esti-
mates from the 2008 and 2009 CAMH Monitor surveys,
and 808,700 people (derived from population estimates
of Ontario in 2010) when based on the 2010 CAMH
Monitor survey[22].
Self-reported non-medical drug use is a subjective
concept, and difficult to measure as it is commonly
under-reported in surveys, with cognitive models of
survey interviews suggesting that reporting errors ori-
ginate from i) poor comprehension of the questions
asked, ii) inaccurate recall of the information, and iii)
deliberate misreporting of information [23]. The
NMPOU questions in the 2008 and 2009 CAMH
Monitor surveys asked about the source and the use
of POA, while the NMPOU question in the 2010
CAMH Monitor survey asked the participant whether
they used prescription opioids without a prescription
or a doctor telling them to do so. Additionally, some
of the NMPOU items may deal with the illicit use
of drugs, a socially disapproved of and unlawful beha-
viour, which may have led participants in the 2008
and 2009 CAMH Monitor surveys to edit their
responses [23-25].Table 3 Odds ratios of non-medical prescription opioid use a
to the 2008 and 2009 CAMH Monitor surveys
Total
Outcome Model Survey
year
Point
estimate
95% Con
interv
Non-medical
prescription opioid use
Model 1
(Unadjusted)
2010 3.99 (2.52 to
2008 and
2009
REF -
Model 2
(Adjusted)
2010 4.12 (2.66 to
2008 and
2009
REF -
Model 2 was adjusted for the following variables: gender (only for the regression in
cigarette smoking, weekly binge drinking, cannabis use (past three months) and psLimitations
It is important to note that NMPOU may have actually
increased and/or the determinants of NMPOU may have
changed between 2008, 2009, and 2010, although it is
highly unlikely that the entirety of the observed differ-
ences in NMPOU prevalence can be explained by these
factors [26]. When comparing the difference in the
NMPOU prevalence in the CAMH Monitor surveys
to the U.S. data for trends in the prevalence of
NMPOU in the same three years (4.8% for 2008, 4.9%
for 2009 and 4.8% for 2010 [11,12,27]), it seems un-
realistic to suggest that the difference found in our
study between 2008/2009 and 2010 is completely at-
tributable to such a major increase in NMPOU. Add-
itionally, to control for a potential change in the
determinants of NMPOU, we performed a regression
analysis that controlled for the covariates of gender
(only for the regression that included both men and
women), age, region, income, prescription opioid use,
cigarette smoking, weekly binge drinking, cannabis
use in the past three months, and psychological dis-
tress, which have been shown to be associated with
NMPOU [28]. Thus, the observed difference in the
prevalence estimates for 2008/2009 versus 2010 is
likely due to measurement error.
Both prevalence estimates of NMPOU are also biased
by factors other than the question used to measure
NMPOU, and thus are likely underestimates of NMPOU
in Ontario. The CAMH Monitor was a telephone-based
population survey and excluded people who did not own
a phone. This excluded group includes homeless indi-
viduals who have been shown to be more likely to
use prescription opioids than the general popula-
tion [29], thereby leading to a probable underestima-
tion of the prevalence of NMPOU. In addition to exclu-
ding people who do not have a phone, the surveys also
excluded people who did not speak either English or
French; however, there were very few people excluded
from the 2008, 2009, or 2010 CAMH Monitor surveyss measured by the 2010 CAMH Monitor survey compared
Men Women
fidence
als
Point
estimate
95% Confidence
intervals
Point
estimate
95% Confidence
intervals
6.31) 3.60 (1.89 to 6.88) 4.58 (2.46 to 8.54)
REF - REF -
6.37) 3.96 (2.27 to 6.93) 4.90 (2.69 to 8.95)
REF - REF -
cluding both men and women), age, region, income, prescription opioid use,
ychological distress.
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16]. An additional difficulty with telephone surveys is that
those people who are unlikely to respond are more likely
to engage in habits that are detrimental to their health
[30]. To obtain accurate estimates of NMPOU in Ontario,
both the question item constructs and protocols used to
calculate these prevalence estimates need to be improved.
Conclusions
The results of this study demonstrate that we cannot be
certain to have a reliable or valid general population sur-
vey estimates of the number of individuals engaging in
NMPOU in Canada. Thus, validity studies investigating
the effects of NMPOU items on a study participant’s
comprehension, interpretation, information retrieval,
judgment formation, and response editing, are needed to
validate current measures and to create improved, stan-
dardized measures of NMPOU in order to generate
more reliable or valid estimates of the number of indivi-
duals engaging in NMPOU in Canada.
In summary, given the morbidity and mortality impact
of NMPOU and the requirement for evidence-based tar-
geted interventions, there is an urgent need to systema-
tically develop, validate, and standardize NMPOU items
for future general population surveys [31].
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